☆ 4.7 Editorial Material

GVHD: better safe than sorry

BLOOD (2023)

Higher Abatacept Exposure Decreases Acute GVHD Risk Without Increasing Adverse Events

Takuto Takahashi et al.

BLOOD (2023)

添加到收藏夹

Article Hematology

Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification

Yun Li et al.

BLOOD REVIEWS (2023)

添加到收藏夹

Review Hematology

Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions

Nuria Martinez-Cibrian et al.

Summary: GvHD, a complication of transplantation, has seen advancements in prevention and treatment, yet challenges remain. Through ongoing research and clinical trials, efforts are being made to find more effective strategies to improve patient outcomes.

BLOOD REVIEWS (2021)

添加到收藏夹

Article Oncology

Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

Benjamin Watkins et al.

Summary: The study showed that adding abatacept to URD HCT was safe and effective in reducing AGVHD and improving SGFS. These results suggest that abatacept may have a significant positive impact on transplant outcomes related to AGVHD, particularly in HLA-mismatched HCT.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Biophysics